A Pharmaceutical Company's Innovative Medicine division needed a clear view of where the world's oncology IP was being built and where the gaps were. Intelacia delivered structured intelligence across 815 applications in under one month.
The oncology drug delivery market was undergoing rapid transformation valued at USD 14.8 billion in 2022 and projected to reach USD 88.5 billion by 2032. The Client's Innovative Medicine division needed a precise, structured view of this landscape: who was filing, where activity was concentrated, and where genuine innovation gaps existed.
Intelacia analysed 815 relevant PCT applications drawn from a pool of ~8,000 filings, delivering a full intelligence synthesis in under one month.
With filing activity surging across universities, biotech startups, and pharmaceutical majors, the IP landscape was dense and difficult to navigate. The client required rigorous, data-backed answers to move with confidence.
Thousands of PCT applications across multiple technology nodes made it difficult to identify where innovation was concentrated and where it was still sparse.
Key academic institutions and life sciences firms were filing aggressively. The client needed to understand where competitors were building IP and where differentiation was possible.
Before committing R&D resources, the team needed a clear view of which technology nodes were saturated and which represented genuine, open innovation opportunities.
With active deal-making across the sector, The client needed a current picture of partnership and acquisition activity to inform its next strategic moves.
Intelacia combined deep patent analytics with market and competitive intelligence structured across five distinct phases.
~8,000 PCT applications were ingested and screened down to 815 in-scope filings. A proprietary 3-tier taxonomy was built across delivery technologies, release types, tumour types, administration routes, and therapeutic agents creating a structured, comparable view across a fragmented landscape.
Each application was tagged across 30+ technology nodes, enabling heat-map analysis of filing density. Nanoparticles, pharmaceutical formulations, liposomes, and injections emerged as dominant nodes, while areas such as dendrimers and magnetic stimuli showed minimal activity.
Top patent assignees were profiled across IP depth, filing velocity, and R&D focus. Prolific inventors were mapped to their institutional affiliations, surfacing talent clusters and signalling emerging research directions within the oncology delivery space.
41 commercial products were reviewed across delivery technologies. 15 M&A and partnership transactions were tracked, and six university-industry collaboration programmes were mapped providing a complete picture of how IP was translating into commercial pipelines and strategic consolidation.
Filing density was cross-referenced with commercial opportunity signals to identify four high-potential whitespace areas dendrimers, stents and rods, magnetic and electrical stimuli-based release, and prodrug-based sustained delivery each flagged for deeper R&D consideration.
The engagement gave Pharmaceutical Company innovation and IP team an evidence-based foundation to guide R&D investment, licensing strategy, and competitive positioning.
A combination of proprietary patent intelligence methods and proven strategic frameworks tailored to the complexity of the oncology IP landscape.
| Framework / Tool | Application |
|---|---|
| Patent Landscape Analysis | 815 relevant PCT applications extracted and classified using a 3-tier proprietary taxonomy across delivery technologies, tumour types, drug agents, and administration routes. |
| Technology Fragmentation Map | Filing trends mapped across 30+ technology nodes to reveal saturation levels and identify genuine whitespace for innovation. |
| Competitive Benchmarking | Top assignees profiled across IP depth, filing velocity, and R&D focus areas to surface competitive concentration and differentiation opportunities. |
| Inventor Intelligence | Prolific inventors mapped to institutional affiliations to identify talent clusters and emerging research directions. |
| Market & M&A Scanning | 41 commercial products and 15 M&A/partnership transactions reviewed to map IP activity against commercial pipelines and strategic consolidation. |
| Technology Gap Analysis | Filing density cross-referenced with market opportunity signals to identify four high-potential whitespace areas. |
| IPC/CPC Class Mapping | Most active patent classification codes decoded to align R&D programmes with convergent global filing trends. |
Intelacia is a strategic intelligence firm specialising in IP analytics, competitive landscaping, and innovation strategy for deep-tech and life sciences organisations helping clients make better, faster decisions on R&D investment, IP positioning, and market entry..
Landscape analyses, competitive benchmarking, and whitespace mapping to guide R&D investment and IP strategy.
Learn more →Patentability searches, FTO analysis, invalidity studies, and state-of-the-art searches across any technology domain.
Learn more →Portfolio analysis, licensing strategy, claim charts, and M&A intelligence to unlock the value in your IP assets.
Learn more →Download Report